Short answer: ipamorelin is one of the few research peptides that has actually been through a randomized, placebo-controlled human trial. In that trial, given intravenously for up to a week after bowel surgery, it was well tolerated: adverse events were no more common than on placebo. It also failed to work for that purpose, which is why it never became a medicine. What the trial cannot tell you is what happens with months of use outside a hospital, which is where the real open questions sit: water retention, blood sugar, and what sustained higher growth-hormone signalling does over time.
What ipamorelin is, and why it was considered “clean”
Ipamorelin is a five-amino-acid peptide developed by Novo Nordisk in the 1990s. It belongs to the growth hormone secretagogues: it activates the ghrelin receptor on the pituitary, which releases a pulse of growth hormone. Older compounds in the same family, such as GHRP-6 and GHRP-2, also raised cortisol and prolactin and caused strong hunger. In the original 1998 characterization, ipamorelin stood out because it released growth hormone without a meaningful rise in ACTH or cortisol, even at high doses in animals. That selectivity is the source of its reputation as the “clean” secretagogue.
“Selective” is a statement about hormones, not a promise of no side effects. Anything that raises growth hormone also raises IGF-1 downstream, and IGF-1 is where most of the long-term questions come from. For how ipamorelin compares with longer-acting options, see CJC-1295 vs tesamorelin vs ipamorelin.
The human trial, in numbers
Ipamorelin was tested for postoperative ileus, the slow return of gut function after abdominal surgery. Beck and colleagues published the phase 2 results in 2014.
| Design | Detail |
|---|---|
| Type | Multicentre, randomized, double-blind, placebo-controlled, phase 2 |
| Participants | 117 adults after bowel resection (114 analysed for safety) |
| Route and duration | Intravenous, twice daily, up to 7 days in hospital |
| Any adverse event | 87.5% ipamorelin vs 94.8% placebo |
| Efficacy | Time to first tolerated meal 25.3 h vs 32.6 h, not statistically significant |
The high adverse-event rates in both groups reflect major surgery, not the drug. The useful signal is that ipamorelin did not add to them. That is a genuine safety data point, with clear limits: one week, in hospital, by IV, in surgical patients.
Hunger, water retention, tingling: the reported effects
| What people report | Is there a mechanism? | How to read it |
|---|---|---|
| Increased hunger | Yes, ghrelin-receptor activation | Milder than with GHRP-6, but plausible. |
| Water retention, puffy hands | Yes, a known growth-hormone effect | The same effect appears on the tesamorelin and growth-hormone labels. |
| Tingling, numbness, wrist pain | Yes, fluid around nerves (carpal tunnel) | A known growth-hormone class effect; persistent symptoms deserve a doctor. |
| Headache, flushing, dizziness | Possible | Anecdotal and unmeasured. |
| Higher fasting blood sugar | Yes, growth hormone opposes insulin | Important for anyone with prediabetes or diabetes. |
Several of these are not specific to ipamorelin. They are effects of raising growth hormone by any route, documented in the labels of approved drugs such as tesamorelin.
The long-term questions
- Blood sugar. Growth hormone makes tissues less sensitive to insulin. With sustained use, that can push glucose up.
- IGF-1 and cell growth. IGF-1 promotes cell growth. Higher IGF-1 levels have been associated with some cancers in population studies. That is not evidence that ipamorelin causes cancer, but it is why GH-raising drugs are contraindicated in people with active cancer.
- Desensitization. Whether the pituitary response fades with constant stimulation has not been measured in long human studies.
Plain version: ipamorelin has a short, clean human safety record in one setting. Its likely side effects are the familiar ones of higher growth hormone. What nobody knows is what months or years of use do.
Health Canada, FDA and WADA
| Health Canada | Not authorized. Ipamorelin is named in Health Canada’s April 2026 advisory on unauthorized injectable peptides and was among products seized from Canada Peptide in 2025. |
|---|---|
| FDA (USA) | Not approved. Development for postoperative ileus stopped after the phase 2 results. |
| WADA (sport) | Prohibited at all times under S2 (growth hormone secretagogues). |
See TrueLabs Ipamorelin and its COA →
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
What are the side effects of ipamorelin?
In a randomized phase 2 trial in 114 surgical patients, adverse events were no more frequent with ipamorelin than with placebo over up to 7 days. Effects linked to raising growth hormone, such as water retention, tingling and higher blood sugar, are plausible with longer use.
Is ipamorelin safe?
Short-term intravenous use was well tolerated in one controlled trial. Long-term safety has not been studied in humans.
Does ipamorelin raise cortisol?
In its original characterization, ipamorelin released growth hormone without a meaningful rise in ACTH or cortisol, unlike older secretagogues such as GHRP-6 and GHRP-2.
Does ipamorelin make you hungry?
It acts on the ghrelin receptor, so increased hunger is plausible, but it is reported as milder than with GHRP-6.
Is ipamorelin legal in Canada?
Ipamorelin is not authorized by Health Canada and is named in its April 2026 advisory on unauthorized injectable peptides.
Is ipamorelin banned in sport?
Yes. WADA prohibits growth hormone secretagogues, including ipamorelin, at all times under S2.
Related reading
- CJC-1295 and ipamorelin: why they are sold together
- CJC-1295 side effects
- CJC-1295 vs tesamorelin vs ipamorelin
- Ipamorelin and CJC-1295 in Canada: research guide
- Tesamorelin side effects: what the drug label shows
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. DOI
- ClinicalTrials.gov. NCT00672074. ClinicalTrials.gov
- Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice. If you have diabetes, prediabetes or a history of cancer, talk to a doctor.